Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

Revision of Precautions

Nivolumab (genetical recombination)

October 12, 2022

Therapeutic category

Other antitumor agents

Non-proprietary name

Nivolumab (genetical recombination)

Safety measure

Precautions should be revised.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Electronic Package Inserts of Prescription Drugs, etc. PSEHB Notification No. 0611-1 by the Director of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 11, 2021 (New instructions): Revised language is underlined.

Current	Revision
8. IMPORTANT PRECAUTIONS <Common to all indications> (N/A)	8. IMPORTANT PRECAUTIONS <Common to all indications> <u>Uveitis may occur. Whether ocular abnormalities have occurred should be examined periodically. In addition, patients should be instructed to immediately seek medical attention if any ocular abnormalities are observed.</u>
11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions (N/A)	11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Uveitis</u>

(N/A) Not Applicable. No corresponding language is included in the current Precautions.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp